Abstract The National Institute of Aging and Alzheimer's Association (NIA-AA) criteria for
Alzheimer disease (AD) treat neuroimaging and cerebrospinal fluid (CSF) markers of AD …

Objective: A workgroup commissioned by the Alzheimer's Association (AA) and the National
Institute on Aging (NIA) recently published research criteria for preclinical Alzheimer disease …

Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …

Objective The new criteria for preclinical Alzheimer disease (AD) proposed 3 stages:
abnormal levels of β‐amyloid (stage 1), stage 1 plus evidence of brain injury (stage 2), and …

Abstract The Alzheimer's Disease Neuroimaging Initiative (ADNI) is an ongoing,
longitudinal, multicenter study designed to develop clinical, imaging, genetic, and …

Objective: Recommendations for the diagnosis of preclinical Alzheimer disease (AD) have
been formulated by a workgroup of the National Institute on Aging and Alzheimer's …

The availability of antemortem biomarkers for Alzheimer's disease (AD) enables monitoring
the evolution of neurodegenerative processes in real time. Pittsburgh compound B (PIB) …

New diagnostic criteria for Alzheimer's disease (AD) treat different biomarkers of neuronal
injury as equivalent. Here, we quantified the degree of agreement between hippocampal …

Neuroimaging biomarkers, namely hippocampal volume loss, temporoparietal
hypometabolism, and neocortical β-amyloid (Aβ) deposition, are included in the recent …

Abstract Purpose of Review: This article reviews recent advances in imaging and fluid
biomarkers for Alzheimer disease (AD) and their application to newly proposed diagnostic …